Publications by authors named "Erika P Hamilton"

Claim this Profile
T
The Second Mitochondria-Derived Activator of Caspases Mimetic BI 891065 in Patients With Advanced Solid Tumors: Results From Two Phase I Studies.
Manish R Patel, Erika P Hamilton, Ben George, Gunther Kretschmar, Akiko Harada

Cancer Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer.
Maxwell R Lloyd, Caroline M Weipert, Azka Ali, Sheila R Solomon, Jayati Saha, Erika P Hamilton

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial to evaluate the safety and immunogenicity of two doses of a folate receptor alpha vaccine in patients with triple negative breast cancer.
Keith L Knutson, Hala Abu-Fares, Patricia Keating, Matthew S Block, Nadine Norton, Erika P Hamilton

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists.
Hope S Rugo, Aditya Bardia, William J Gradishar, Erika P Hamilton, Sara A Hurvitz

Breast· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.
Mario Campone, Michelino De Laurentiis, Komal Jhaveri, Xichun Hu, Sylvain Ladoire, Erika P Hamilton

N Engl J Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study results.
Erika P Hamilton, Manish R Patel, Virginia F Borges, Jane L Meisel, Meena Okera

Breast Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Erika P Hamilton, Rinath M Jeselsohn, Linda T Vahdat, Sara A Hurvitz

Target Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.
Alicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno, Do-Youn Oh, Andree Rorive, Erika P Hamilton

Nat Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer.
Erika P Hamilton, Sibylle Loibl, Thomas Bachelot, Michael Gnant, Naoki Niikura

Future Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors.
Manish R Patel, Gerald S Falchook, Judy S Wang, Esteban Rodrigo Imedio, Sanjeev Kumar, Erika P Hamilton

Target Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.
Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn, Cynthia X Ma, Erika P Hamilton

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.
Erika P Hamilton, Gerald S Falchook, Judy S Wang, Siqing Fu, Amit M Oza

Target Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer.
Erika P Hamilton, Cynthia Ma, Michelino De Laurentiis, Hiroji Iwata, Sara A Hurvitz

Future Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika P Hamilton

J Clin Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.
Matthew P Goetz, Erika P Hamilton, Mario Campone, Sara A Hurvitz, Javier Cortes

Clin Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, Frances Boyle, Javier Cortes, Erika P Hamilton

J Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
Andreas Varkaris, Ermira Pazolli, Hakan Gunaydin, Qi Wang, Levi Pierce, Erika P Hamilton

Cancer Discov· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breaking Barriers: Integrating Germline Testing With Oncology Care.
Mythili Shastry, Marilyn E Hammer, Andrew J McKenzie, Erika P Hamilton

JCO Oncol Pract· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
Ignace Vergote, Jose Alejandro Pérez-Fidalgo, Erika Paige Hamilton, Giorgio Valabrega, Toon Van Gorp

J Clin Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma.
Erika P Hamilton, Judy S Wang, Amit M Oza, Manish R Patel, Susanna V Ulahannan

Mol Cancer Ther· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
Arvind Dasari, Erika P Hamilton, Gerald S Falchook, Judy S Wang, Daneng Li

Invest New Drugs· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel endocrine therapy agents in ER-positive, HER2-negative breast cancer.
Erika P Hamilton

Clin Adv Hematol Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
Siqing Fu, Bradley R Corr, Kerry Culm-Merdek, Colleen Mockbee, Hagop Youssoufian, Erika Paige Hamilton

J Clin Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage.
Gilberto Morgan, Neeraj Agarwal, Toni K Choueiri, Don S Dizon, Erika P Hamilton

Cancer Discov· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New approaches to endocrine therapy in ER-positive, HER2-negative breast cancer.
Erika P Hamilton

Clin Adv Hematol Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis